Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK, Vir Biotechnology to expand Covid-19 treatment study
The companies announced the global expansion to phase 3 of the Covid-19 monoclonal antibody efficacy trial – intent to care early (COMET-ICE) to assess VIR-7831 for the early
The companies announced the global expansion to phase 3 of the Covid-19 monoclonal antibody efficacy trial – intent to care early (COMET-ICE) to assess VIR-7831 for the early
Under the deal, Scribe Therapeutics and Biogen will develop and commercialise CRISPR-based therapies to treat amyotrophic lateral sclerosis (ALS). X-Editing (XE), which is Scribe’s first technology, is said
“The FDA’s designation recognizes the morbidity and mortality burdens of sickle cell disease as well as its significant impact during childhood with life-long implications. With this designation, the
MyoKardia is engaged in the discovery and development of targeted therapies to treat serious cardiovascular diseases. As per terms of the merger deal, BMS subsidiary will begin a
FDA has provided the breakthrough therapy status based on data from the BPDCN cohort of the first-in-human study of IMGN632, said ImmunoGen. IMGN632 is a CD123-targeting ADC, which
The deal is valued at around $647m on an enterprise basis, including debt obligations expected to be assumed or repaid net of cash. As per terms of the
Under the deal, CStone and Pfizer will involve in the development and commercialisation of CStone’s sugemalimab, an investigational anti-PD-L1 monoclonal antibody, in mainland China. They will also co-develop
Mesenchymal stem cells hold great promise to treat COVID-19 patients due to their potential in inhibiting the overactivated immune system and promoting the recovery of pulmonary and other
Earlier this year Infinity also received Fast Track designation for eganelisib in combination with the checkpoint inhibitor Opdivo® for the treatment of advanced urothelial cancer which the company
The randomised, double-blind, exploratory phase I trial A has been designed to evaluate the pharmacokinetic profile, safety and tolerability of a continuous daily dosing regimen of Ivermectin in